Back to Search Start Over

MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab

Authors :
Bourdin, Arnaud
Chupp, Geoffrey
Jackson, David J.
Cohen, David
Emerath, Ulrika
Shavit, Anat
Kurdyukova, Yulia
Menzies-Gow, Andrew
Source :
The Journal of Allergy and Clinical Immunology: In Practice; August 2024, Vol. 12 Issue: 8 p2074-2083.e4
Publication Year :
2024

Abstract

Benralizumab and mepolizumab are interleukin (IL)-5Rα/interleukin-5–targeted monoclonal antibodies indicated as add-on treatments for patients with uncontrolled severe eosinophilic asthma (SEA).

Details

Language :
English
ISSN :
22132198
Volume :
12
Issue :
8
Database :
Supplemental Index
Journal :
The Journal of Allergy and Clinical Immunology: In Practice
Publication Type :
Periodical
Accession number :
ejs66170041
Full Text :
https://doi.org/10.1016/j.jaip.2024.04.033